Intravitreal aflibercept for proliferative diabetic retinopathy - Authors' reply

Affiliations

¹ National Institute for Health Research, Moorfields Biomedical Research Centre, London EC1V 2PD, UK. Electronic address: Sobha.sivaprasad@moorfields.nhs.uk.
² Imperial Clinical Trials Unit, School of Public Health, Imperial College London, London, UK.
³ King's Clinical Trials Unit at King's Health Partners, King's College London, London, UK.
⁴ National Institute for Health Research, Moorfields Biomedical Research Centre, London EC1V 2PD, UK.

Comment

Sobha Sivaprasad et al. Lancet. 2017.

. 2017 Nov 11;390(10108):2141-2142.

doi: 10.1016/S0140-6736(17)32422-4. Epub 2017 Nov 9.

¹ National Institute for Health Research, Moorfields Biomedical Research Centre, London EC1V 2PD, UK. Electronic address: Sobha.sivaprasad@moorfields.nhs.uk.
² Imperial Clinical Trials Unit, School of Public Health, Imperial College London, London, UK.
³ King's Clinical Trials Unit at King's Health Partners, King's College London, London, UK.
⁴ National Institute for Health Research, Moorfields Biomedical Research Centre, London EC1V 2PD, UK.

No abstract available

Comment on

Intravitreal aflibercept for proliferative diabetic retinopathy.
Liu L, Tham YC, Cheng CY. Liu L, et al. Lancet. 2017 Nov 11;390(10108):2140-2141. doi: 10.1016/S0140-6736(17)32426-1. Epub 2017 Nov 9. Lancet. 2017. PMID: 29143751 No abstract available.
Intravitreal aflibercept for proliferative diabetic retinopathy.
Brown DM, Wykoff CC. Brown DM, et al. Lancet. 2017 Nov 11;390(10108):2141. doi: 10.1016/S0140-6736(17)32445-5. Epub 2017 Nov 9. Lancet. 2017. PMID: 29143753 No abstract available.